Growth hormone release after glucagon as a reliable test of growth hormone assessment in adults

被引:93
作者
Gómez, JM
Espadero, RM
Escobar-Jiménez, F
Hawkins, F
Picó, A
Herrera-Pombo, JL
Vilardell, E
Durán, A
Mesa, J
Faure, E
Sanmartí, A
机构
[1] Hosp Princeps Espanya, Endocrine Unit, Barcelona, Spain
[2] Pharmacia, Endocrine Unit, Madrid, Spain
[3] Hosp Clin San Cicilio Granada, Endocrine Unit, Granada, Spain
[4] Hosp Doce Octubre Madrid, Endocrine Unit, Madrid, Spain
[5] Hosp Gen Alacant, Endocrine Unit, Albacete, Spain
[6] Fdn Jimenez Diaz, Endocrine Unit, Madrid, Spain
[7] Hosp Clin Barcelona, Endocrine Unit, Barcelona, Spain
[8] Hosp Clin Madrid, Endocrine Unit, Madrid, Spain
[9] Hosp Gen Valle Hebron, Endocrine Unit, Barcelona, Spain
[10] Hosp Clin, Endocrine Unit, Zaragoza, Spain
[11] Hosp Badalona Germans Trias & Pujol, Endocrine Unit, Badalona, Spain
关键词
D O I
10.1046/j.1365-2265.2002.01472.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To investigate the GH response to glucagon in adult patients with GH deficiency and in controls compared with the GH response to the insulin tolerance test (ITT) in patients with GH deficiency and to determine whether the use of glucagon results in a diagnostic utility test. PATIENTS AND DESIGN Seventy-three patients with adult GH deficiency and organic hypothalamic-pituitary disease were recruited, along with 46 controls. The patients were divided into five groups according to the number of associated hormone deficiencies present. MEASUREMENTS Hypopituitary subjects underwent assessment of GH secretory status by the ITT, the glucagon test and measurement of serum IGF-I concentration. Controls underwent the glucagon test. After the ITT, glucose and GH levels were measured at baseline, 30, 60 and 90 minutes, and after glucagon at baseline, 90,120,150,180, 210 and 240 minutes. RESULTS The highest GH value after the ITT in the patient group was 3 mug/l (0.76 +/- 0.82 mug/l), and after the glucagon test the highest GH peak value was 2.9 mug/l (0.64 +/- 0.79 mug/l). A correlation was found between the GH peak and the progressive number of hormone deficiencies. After the glucagon test, the GH peak obtained in the controls at 180 minutes was 9.8 +/- 4.6 mug/l and, on an individual basis, none of the 46 controls failed to achieve peak GH levels higher than 3 mug/l. In the controls, a negative correlation was observed between the GH response to glucagon and age (r = -0.389, P = 0.0075) and body mass index (r = -0.329, P = 0.0254). The accuracy of the glucagon test for differentiating patients from controls, estimated by receiver operating characteristics (ROC) curve methodology, showed that the cut-off of 3 mug/l for the GH peak provides 100% sensitivity and 100% specificity and is a reliable decision threshold. CONCLUSIONS The glucagon GH test is reliable and provides a clear separation between GH-deficient and normal adults. A single glucagon test with a cut-off of 3 mug/l for the GH peak is diagnostic of GH deficiency in adults and could be considered and studied as an alternative to the ITT.
引用
收藏
页码:329 / 334
页数:6
相关论文
共 30 条
[1]   The study of spontaneous GH secretion after 36-h fasting distinguishes between GH-deficient and normal adults [J].
Aimaretti, G ;
Colao, A ;
Corneli, G ;
Pivonello, R ;
Maccario, M ;
Morrison, K ;
Pflaum, CD ;
Strasburger, CJ ;
Lombardi, G ;
Ghigo, E .
CLINICAL ENDOCRINOLOGY, 1999, 51 (06) :771-777
[2]   Interaction between glucagon and Hexarelin, a peptidyl GH secretagogue, on somatotroph and corticotroph secretion in humans [J].
Arvat, E ;
Maccagno, B ;
Ramunni, J ;
Giordano, R ;
Broglio, F ;
Gianotti, L ;
Maccario, M ;
Camanni, F ;
Ghigo, E .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2000, 143 (05) :601-606
[3]   VALUE AND LIMITS OF PHARMACOLOGICAL AND PHYSIOLOGICAL TESTS TO DIAGNOSE GROWTH-HORMONE (GH) DEFICIENCY AND PREDICT THERAPY RESPONSE - FIRST AND 2ND RETESTING DURING REPLACEMENT THERAPY OF PATIENTS DEFINED AS GH DEFICIENT [J].
CACCIARI, E ;
TASSONI, P ;
CICOGNANI, A ;
PIRAZZOLI, P ;
SALARDI, S ;
BALSAMO, A ;
CASSIO, A ;
ZUCCHINI, S ;
COLLI, C ;
TASSINARI, D ;
TANI, G ;
GUALANDI, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (06) :1663-1669
[4]  
CAIN JP, 1972, CAN MED ASSOC J, V107, P617
[5]   CLINICAL ASPECTS OF GROWTH-HORMONE DEFICIENCY IN ADULTS [J].
DEBOER, H ;
BLOK, GJ ;
VANDERVEEN, EA .
ENDOCRINE REVIEWS, 1995, 16 (01) :63-86
[6]   PULSATILE GROWTH-HORMONE RELEASE IN NORMAL WOMEN DURING THE MENSTRUAL-CYCLE [J].
FARIA, ACS ;
BEKENSTEIN, LW ;
BOOTH, RA ;
VACCARO, VA ;
ASPLIN, CM ;
VELDHUIS, JD ;
THORNER, MO ;
EVANS, WS .
CLINICAL ENDOCRINOLOGY, 1992, 36 (06) :591-596
[7]  
Fisker S, 1998, CLIN ENDOCRINOL, V48, P109
[8]   New approach to the diagnosis of growth hormone deficiency in adults [J].
Ghigo, E ;
Aimaretti, G ;
Gianotti, L ;
Bellone, J ;
Arvat, E ;
Camanni, F .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1996, 134 (03) :352-356
[9]   Diagnostic efficiency of serum IGF-I, IGF-binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and urinary GH measurements in the diagnosis of adult GH deficiency: importance of an appropriate reference population [J].
Granada, ML ;
Murillo, J ;
Lucas, A ;
Salinas, I ;
Llopis, MA ;
Castells, I ;
Foz, M ;
Sanmarti, A .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2000, 142 (03) :243-253
[10]  
*GROWTH HORM RES S, 1999, J CLIN ENDOCR METAB, V83, P379